gemcitabine drla gemcitabine (as hydrochloride) 2 g powder for injection vial
dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 2277 mg (equivalent: gemcitabine, qty 2000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide; sodium acetate trihydrate - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.
gemcitabine ebewe gemcitabine (as hydrochloride) 1000 mg powder for injection vial
sandoz pty ltd - gemcitabine hydrochloride, quantity: 1140 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; sodium hydroxide; mannitol - gemcitabine ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (nsclc) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
gemcitabine ebewe gemcitabine (as hydrochloride) 200 mg powder for injection vial
sandoz pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - gemcitabine ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (nsclc) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
gemcitabine hydrochloride for injection powder for solution
sandoz canada incorporated - gemcitabine (gemcitabine hydrochloride) - powder for solution - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents
gemcitabine hydrochloride for injection powder for solution
sandoz canada incorporated - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents
gemcitabine injection solution
sandoz canada incorporated - gemcitabine (gemcitabine hydrochloride) - solution - 40mg - gemcitabine (gemcitabine hydrochloride) 40mg - antineoplastic agents
gemaccord gemcitabine (as hydrochloride) 1000 mg powder for injection vial
accord healthcare pty ltd - gemcitabine hydrochloride (equivalent: gemcitabine, qty 1 g) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with 5-fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.
gemcitabine for injection concentrate solution
accord healthcare inc - gemcitabine (gemcitabine hydrochloride) - solution - 100mg - gemcitabine (gemcitabine hydrochloride) 100mg - antineoplastic agents
gemcitabine 100mg/ml concentrate for solution for infusion concentrate for solution for i/v infusion
accord healthcare limited - gemcitabine (gemcitabine hydrochloride) - concentrate for solution for i/v infusion - 100mg/ml
gemcitabine 100mg/ml concentrate for solution for infusion concentrate for solution for i/v infusion
accord healthcare limited - gemcitabine (gemcitabine hydrochloride) - concentrate for solution for i/v infusion - 100mg/ml